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Abstract
Background: Chronic neuroinflammation is implicated in Parkinson's disease (PD). Inflammation involves
the activation of microglia and astrocytes that release high levels of prostaglandins. There is a profound
gap in our understanding of how cyclooxygenases and their prostaglandin products redirect cellular events
to promote PD neurodegeneration. The major prostaglandin in the mammalian brain is prostaglandin D2,
which readily undergoes spontaneous dehydration to generate the bioactive cyclopentenone
prostaglandins of the J2 series. These J2 prostaglandins are highly reactive and neurotoxic products of
inflammation shown in cellular models to impair the ubiquitin/proteasome pathway and cause the
accumulation of ubiquitinated proteins. PD is a disorder that exhibits accumulation of ubiquitinated
proteins in neuronal inclusions (Lewy bodies). The role of J2 prostaglandins in promoting PD
neurodegeneration has not been investigated under in vivo conditions.
Methods: We addressed the neurodegenerative and behavioral effects of the administration of
prostaglandin J2 (PGJ2) simultaneously into the substantia nigra/striatum of adult male FVB mice by
subchronic microinjections. One group received unilateral injections of DMSO (vehicle, n = 6) and three
groups received PGJ2 [3.4 μg or 6.7 μg (n = 6 per group) or 16.7 μg (n = 5)] per injection.
Immunohistochemical and behavioral analyses were applied to assess the effects of the subchronic PGJ2
microinfusions.
Results: Immunohistochemical analysis demonstrated a PGJ2 dose-dependent significant and selective
loss of dopaminergic neurons in the substantia nigra while the GABAergic neurons were spared. PGJ2 also
triggered formation of aggregates immunoreactive for ubiquitin and α-synuclein in the spared
dopaminergic neurons. Moreover, PGJ2 infusion caused a massive microglia and astrocyte activation that
could initiate a deleterious cascade leading to self-sustained progressive neurodegeneration. The PGJ2-
treated mice also exhibited locomotor and posture impairment.
Conclusion: Our studies establish the first model of inflammation in which administration of an
endogenous highly reactive product of inflammation, PGJ2, recapitulates key aspects of PD. Our novel
PGJ2-induced PD model strongly supports the view that localized and chronic production of highly
reactive and neurotoxic prostaglandins, such as PGJ2, in the CNS could be an integral component of
inflammation triggered by insults evoked by physical, chemical or microbial stimuli and thus establishes a
link between neuroinflammation and PD neurodegeneration.
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Background
There is increasing recognition that neuroinflammation is
a major factor in the pathogenesis of neurodegenerative
disorders such as Alzheimer's [1] and Parkinson's (PD)
[2,3]. In particular, evidence suggests that prior occur-
rence of inflammation in the brain, due to either brain
injury or infectious agents, may play a key role in PD
pathogenesis [4]. It is proposed that a self-perpetuating
cycle of inflammatory processes involving brain immune
cells (microglia and astrocytes) may drive the slow pro-
gression of the neurodegenerative process. The neuroin-
flammation hypothesis for PD is supported by different
kinds of evidence (reviewed in [5]) such as (1) increased
numbers of astrocytes and microglia in affected brain
areas as well as continued presence of activated microglia
in the substantia nigra; (2) DNA polymorphisms in
cytokines modify PD risk, in particular the age of onset;
(3) protection by non-steroidal anti-inflammatory drugs
(NSAIDs) although this is highly controversial, and (4)
most in vivo and in vitro models of PD support involve-
ment of inflammatory mechanisms. Many of the animal
models for idiopathic PD are produced by neurotoxins,
the four most popular being 6-hydroxydopamine (6-
OHDA), MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropy-
ridine), rotenone and paraquat [6]. All of these animal
models are associated with signs of neuroinflammation in
the substantia nigra, supporting the view that inflamma-
tion and in particular glial cells including astrocytes and
microglia, play a central role in PD [5].
It is thought that the dopaminergic neurons in the substan-
tia nigra pars compacta (SNpc) are particularly sensitive to
injury because they have mitochondrial defects [7],
reduced anti-oxidant capacity (such as low reduced glu-
tathione levels), and high content of dopamine, melanin
and lipids, which are all prone to oxidation [4]. In addi-
tion, the SN is particularly rich in microglia [8], which
once activated could provide for a potentially damaging
environment surrounding the neurons in that area of the
brain [4].
To directly test the hypothesis that inflammation in the
brain can lead to selective loss of dopaminergic neurons,
several groups used lipopolysaccharide (LPS) either (i)
chronically or acutely infused into the substantia nigra
[9,10]; or (ii) through an in utero exposure of developing
fetuses to the endotoxin [11]. In the first paradigm, micro-
glia activation preceded dopaminergic loss [9,10] and in
the second one selective degeneration of the nigrostriatal
dopaminergic pathway was observed in the neonates [11].
These studies provide a potential mechanistic link
between inflammation in the brain and dopaminergic
neurodegeneration [4]. The LPS models of PD address the
central role of inflammation in this disease but they do
not distinguish which of the factors produced by activated
microglia and astrocytes induce neurodegeneration. This
is a very important issue since the mechanisms by which
activated glia specifically target dopaminergic neurons
remain critical missing links in the proof of a pathogenic
role for activated glia in PD.
Prostaglandins are largely produced by activated micro-
glia and reactive astrocytes (less by neurons) in neuroin-
flammation. Prostaglandins act as potent local regulators
of pathogenic processes associated with CNS inflamma-
tion. Our new PGJ2-induced PD model supports the
hypothesis that localized production of highly reactive
and neurotoxic cyclopentenone PGJ2 may be one of such
links between activated glia and PD pathogenesis. Herein,
we present in vivo evidence for a role of PGJ2 in the death
of dopaminergic neurons in the SNpc. We also show that
in this dopaminergic neuronal population, PGJ2 induces
the formation of ubiquitin-protein aggregates containing
TH and α-synuclein. Furthermore, PGJ2 leads to micro-
glial and astrocyte activation. This feed-forward cycle of
glial activation and neuronal injury could be a driving
force for progressive dopaminergic neurodegeneration
observed in PD.
Methods
Animals
Male FVB mice, 11-week old weighing 33 g to 39 g, were
obtained from Taconic Farms, Germantown, NY. Mice
were singly housed on a 12-h light/dark cycle with food
and water available ad libitum. The room temperature was
maintained at 23°C and 50–70% humidity. Animals were
habituated for two weeks before commencement of sur-
gery, which was initiated at 13 weeks of age. All mice were
treated in accordance with the guidelines for Animal Care
Use at NIH. All efforts were made to reduce animal suffer-
ing and the number of animals used.
A total of 23 mice received unilateral injections of PGJ2 or
vehicle (DMSO) into the striatum and SN simultaneously.
The experiments were carried out in four groups of mice.
One group received DMSO/PBS (n = 6) and three groups
received PGJ2 concentration of 3.4 μg, 6.7 μg or 16.7 μg
PGJ2 in DMSO/PBS per injection (n = 6 per group, except
the last concentration n = 5), respectively (Fig. 1). Each
mouse served as its own control, since there was no sur-
gery on its left-side (contralateral to the lesion). In addi-
tion, mice injected with DMSO/PBS served as controls for
PGJ2 infusion, since they received unilateral injections of
DMSO/PBS solution. Upon microinjection some nonspe-
cific damage (gliosis) was seen at the site of injection (Fig.
1, star indicates site of injection). The injection site is not
evident in most of the other figures because they were
taken in planes different from the injected one.
DMSO (dimethyl sulfoxide) was the solvent for PGJ2 and
its final concentration was 17% for all microinfusions.
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The solutions were freshly prepared and stored for a max-
imum of 2 h under cold (4°C) and dark conditions.
Choice of PGJ2 dose and frequency
PGJ2 was from Cayman Chemical (Ann Arbor, MI). Cur-
rently available methods to measure PGJ2 levels in cells or
in human tissues and fluids are likely to lead to an under-
representation of its total amounts formed and will not
reflect its biological activity [12]. This is because PGJ2 is
highly reactive with thiol-containing intracellular compo-
nents like glutathione or thiol-containing proteins via
Michael addition [13]. It is possible however to estimate
the rate of formation of PGJ2 from PGD2 tissue concen-
trations as PGJ2 is formed from PGD2 by a non-enzy-
matic first order dehydration reaction. Notably, PGD2
synthesis in mouse brain increased under stress condi-
tions from ~17 pmoles/g brain to ~102 pmoles/g of brain
(a six-fold increase) as a result of only a 30 second
hypoxia [14]. In addition, microglia PGD2 levels
increased 23-fold upon activation with a calcium iono-
phore [15]. These findings support the view that PGD2
synthesis is extraordinarily dynamic and consequently
A. Schematic representation of the experimental designFigur  1
A. Schematic representation of the experimental design. Subchronic microinjections into the right substantia nigra and 
striatum were processed at 13, 17, 18 and 19 weeks of age. Mice (four groups) were microinjected with either DMSO/PBS 
(vehicle) or three concentrations of PGJ2/PBS (3.4 μg, 6.7 μg or 16.7 μg) per injection. All animals were perfused intracardially 
for pathohistological examinations at 23 weeks of age, thus four weeks after the last injection. Behavioral tests were performed 
four weeks after the last microinjection. B – Site of injection. Immunofluorescence analysis with anti-tyrosine hydroxylase 
(red, dopaminergic neuronal marker) and anti-IBA1 (green, activated microglia marker) antibodies revealed nonspecific damage 
at the site of injection in a mouse infused with DMSO/PBS (vehicle). The star indicates the site of injection. Scale bar = 100 μm.
Journal of Neuroinflammation 2009, 6:18 http://www.jneuroinflammation.com/content/6/1/18
Page 4 of 12
(page number not for citation purposes)
PGJ2 levels are likely to also increase significantly during
inflammation.
Activated astrocytes and microglia make large quantities
of prostaglandins such as PGE2 and PGD2 [4] as well as
PGJ2 [16]. There is no available means to specifically
increase endogenous PGJ2 levels because PGJ2 is sponta-
neously derived from PGD2 by non-enzymatic dehydra-
tion. Thus to assess the effects of increases in PGJ2 we
infused it directly into the brain.
In choosing the PGJ2 concentrations for infusion we had
to consider that (1) the injected pool of PGJ2 would be in
equilibrium via active transport [17,18] with the blood
circulating through the injected area, and (2) that PGJ2
binds very quickly to blood albumin, leading to a contin-
uous removal of PGJ2 from the site of injection. In one
study it was estimated in cell cultures that ten percent fetal
bovine serum reduces the concentration of PGJ2 available
to cells by 150-fold, by directly and reversibly interacting
with PGJ2 and sequestering it in the medium [19]. The lat-
ter study also demonstrated that human serum had simi-
lar PGJ2-sequestration properties. Moreover, due to slight
hemorrhage at the site of injection, the released serum
albumin will bind some of the injected PGJ2, leading to a
further reduction of the available PGJ2. Consequently, the
amounts of PGJ2 that diffuse into to the brain tissue con-
tiguous to the site of injection are bound to be signifi-
cantly lower than those initially infused.
In addition, we wanted to establish a progressive PD
model, one in which there is a progressive loss of SNpc
dopaminergic neurons. In a recent study, 8 μg of 6-OHDA
were bilaterally infused into mouse striatum daily for 5
days [20]. This subchronic paradigm provoked a moder-
ate, but significant loss of nigral neurons while a single
injection did not. All of these studies support our choice
to infuse the mice unilaterally with three concentrations
(3.4 μg, 6.7 μg and 16.7 μg per injection) of PGJ2, similar
to the 6-OHDA concentration in the study described
above.
All animals received four microinfusions per site of injec-
tion at the following ages: initial injections were given at
13 weeks of age followed by individual injections at 17,
18 and 19 weeks of age (Fig. 1). Our reasoning was that by
giving a total of four injections per site, we would mimic
to a certain extent subchronic inflammation.
Surgery and "subchronic" microinfusion
Mice were anesthetized with 2.5% isoflurane in oxygen
(0.6 L/min flow rate) and placed in a stererotaxic frame
(Model 5000 Small Animal Stereotaxic Instrument; Kopf
Instruments) fitted with a mouse anesthesia mask (Model
907, David Kopf instruments). A 2 μl Hamilton microin-
jection syringe (7002 KH) with a 25-gauge needle was
attached to the stereotaxic frame via a Universal Holder
(David Kopf Instruments). Holes were drilled into the
skull and the needle moved to the injection site and
inserted slowly. Unilateral (right side) injection sites were
determined using a mouse brain atlas [21]. The following
coordinates were used relative to bregma: substantia nigra,
RC -3.25 mm; ML ± 1.25 mm; DV +4.13 mm; striatum, RC
+0.5 mm; ML ± 2.0; DL +2.5 mm. The needle was left in
position for 5-min before two μl of the desired solution
were injected into the right side over 10-min (~0.2 μl/
min). At the end of the injection, the incision was sutured.
The mouse was removed from the stereotaxic apparatus,
given a subcutaneous injection of one ml of sterile saline,
and left in a warm place to recover. Multiple injections
were administered using the same cranial openings drilled
at the initial microinjection sites. After each microinjec-
tion the incision was sutured and swabbed with betadine
solution. Animals were continuously monitored by the
staff veterinarian and no signs of infections were noted.
Immunohistochemistry
For immunohistochemical analysis mice were perfused at
23 weeks of age, thus four weeks after the last injection.
Mice were anesthetized using a lethal dose of ketamine/
Ace (100/3 mg/kg of body weight, intraperitoneal) and
perfused intracardially with 60 ml of Tyrode (RT), fol-
lowed by fixative (4% paraformaldehyde, 7% saturated
picric acid, 0.1% glutaraldehyde in PBS at 4°C). Brains
were removed, postfixed for two hours in the same fixative
at RT, and cryopreserved in 15% sucrose overnight at 4°C.
They were then frozen in dry ice and stored at -80°C until
further analysis. Free-floating coronal sections (30 μm
thick) from the substantia nigra were cut on a sliding
microtome HM440E (Microm, Waldorf, Germany).
For immunostaining, sections were permeabilized by
sequentially washing with TBS containing 0.5% Triton X-
100 (TBS-T)/TBS/TBS-T for 10-min each. Sections were
then incubated with the primary antibodies in TBS-T over-
night at 4°C and washed again as above. The sections
were then incubated for 90-min with the first appropriate
labeled secondary antibody (anti-mouse or anti-rabbit
antibody, 1:100) in TBS-T and washed again. For sections
that were triple stained, tissues were incubated with a sec-
ond secondary antibody (anti-mouse or anti-rabbit,
1:100) for an additional 90-min, followed by three
washes with TBS (10-min each), incubation with Hoechst
33342 (a nuclear stain, 1:500 in TBS) for 30-min and
three final washes with TBS. Sections were mounted on
glass slides, using 80% glycerol in TBS. Cell staining was
visualized with a Leica TCS SP2 confocal microscope
(Leica microsystems, Exton, PA). Symmetric areas from
injected and control (contralateral, left side) sides as well
as DMSO/PBS and PGJ2/PBS injected (ipsilateral) sides
were compared.
Journal of Neuroinflammation 2009, 6:18 http://www.jneuroinflammation.com/content/6/1/18
Page 5 of 12
(page number not for citation purposes)
Primary antibodies: dopaminergic neurons [tyrosine
hydroxylase (TH+), 1:500, Abcam (Cambridge, MA),
ab6211, rabbit or 1:50, TOHA1.1, mouse, kindly supplied
by Dr. C. Cuello, McGuill University, Canada]; neurons
[NeuN, 1:50, Chemicon (Temecula, CA), mab377,
mouse]; GABAergic neurons [GAD67, 1:1,000, Chemicon
(Temecula, CA), mab5406, mouse]; ubiquitin inclusions
[ubiquitinated proteins, 1:200, Dako Cytomation
(Carpinteria, CA), Z0458, rabbit]; α-synuclein [1:250, BD
Transduction (San Jose, CA), 610787, mouse]; microglia
[IBA1, 1:500, Wako Chemicals (Richmond, VA), 019–
19741, rabbit]; astrocytes [GFAP, 1:500, Sigma-Aldrich
(St. Louis, MO) G3893, mouse]. Secondary antibodies:
anti-rabbit Alexa 594, A21207, anti-mouse Alexa 488,
A21206, and anti-mouse Alexa 350, S11249, all from
Molecular Probes, Carslbad, CA and anti-mouse CY3,
1:200, from Amersham Biosciences, Piscataway, NJ.
Cell counts: the number of TH+ cells was determined
using a computer-assisted image analysis system, consist-
ing of an Axiophot photomicroscope (Carl Zeiss Vision,
Hallbergmoos, Germany) comprising a Zeiss plana-
pochromat 100 × oil objective equipped with a computer-
controlled motorized stage, a video camera, and the
Stereo Investigator software (MicroBrightField, Williston,
VT). The number of TH+ cells was counted in 6–8 sec-
tions/mouse (BREGMA coordinates -2.54/-3.64) on the
delineated SNpc (ipsilateral, right side). We compared
TH+ cell numbers in five DMSO-infused mice with those
of five mice infused with 16.7 μg PGJ2 because the latter
group of mice showed the greatest degree of change.
Means and S.E. for each of the two groups (DMSO and
PGJ2-treated) were determined and the p value calculated
with the two-tailed test.
Animal behavior
Simple behavioral tests in control and PGJ2-treated mice
were performed four weeks after the last injection. Asym-
metry in body posture and gait abnormalities were tested
with the curling test and the footprint test, respectively.
The degree of nigrostriatal damage was assessed with the
turning behavior test.
1) Curling
The curling test evaluates any asymmetry in body posture
[22]. The mouse was lifted gently two cm above the bed-
ding for 5-sec and any ipsilateral deviation from its verti-
cal body axis of 10° or greater was recorded. The test was
repeated three times for each animal.
2) Footprint test
Mice were placed in a 5-cm wide, 85-cm long corridor.
The floor of this corridor was covered with white absorb-
ing paper. The animals were first trained to pass straight
forward through the corridor. After this training, the paws
were colored with different colors (red for the forepaws
and black for the hindpaws), and the mice were then
placed into the corridor [20]. Step frequency and stride
length were determined with the program Footprints ver-
sion 1.22 [23].
3) Asymmetric circling motor behavior
This behavior is dependent on the degree of nigrostriatal
damage. We tested for this behavior upon administration
of apomorphine, a dopamine receptor agonist. Rotation is
more prominent after apomorphine (APO, Sigma-
Aldrich, St. Louis, MO) due to imbalance between
lesioned and unlesioned hemispheres [6]. APO leads to a
reversal of rodent asymmetry, in that the animals which
otherwise have an ipsiversive asymmetry now turn contra-
versively. Furthermore, the induction of contraversive
turning occurs rapidly within minutes after drug adminis-
tration [24,25]. APO was administered (1.5 mg/kg, intra-
peritoneally) to reverse animal asymmetry to determine
whether this behavior is indeed due to SN damage and
not disruption of a different sort of neighboring cell type.
Results
PGJ2-microinfused mice exhibited loss of dopaminergic 
neurons in the SNpc but the GABAergic neurons in the 
SNpr were spared
To assess the vulnerability of nigral dopaminergic neu-
rons to the neurotoxic prostaglandin PGJ2, FVB mice
received four injections of PGJ2 at 13, 17, 18 and 19
weeks of age. Mice were processed for immunohistochem-
ical analysis four weeks after the last injection. At 23 weeks
of age TH+ staining showed loss of SNpc dopaminergic
neurons in a dose-dependent manner (Fig. 2, immunoflu-
orescence staining). Mice infused with 16.7 μg PGJ2
exhibited an estimated 85% decrease in TH+ cells in the
ipsilateral SNpc, compared to DMSO-infused mice (see
the table in Fig. 3). That the loss of TH staining was due to
neuronal loss and not to TH down-regulation is asserted
by the PGJ2 concentration-dependent loss of NeuN neu-
ronal staining (Fig. 3).
One of the most challenging aspects of PD is to explain
why the dopaminergic neurons in the SNpc are particu-
larly vulnerable to neurodegeneration. One possibility is
that the susceptibility to stress conditions is exacerbated
by the pro-oxidant properties of dopamine. In fact, we
observed that the GABAergic neurons of the substantia
nigra pars reticulata (SNpr) were spared (Fig. 4) even in
mice treated with the highest (16.7 μg) PGJ2-concentra-
tion. These data support that SNpc dopaminergic neurons
are indeed more sensitive to the neurotoxic effects of PGJ2
than the neighboring GABAergic neurons in the SNpr.
To rule out the possibility that the prostaglandin did not
reach the SNpr, we validated our infusion protocol by
injecting equivalent amounts of the dyes methylene blue
(water soluble) or Sudan black (water insoluble) to mimic
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the conditions used to inject PGJ2. Upon sectioning, it
was clear that both dyes reached the SNpc as well as the
SNpr (not shown).
Detection of aggregates with ubiquitinated proteins and α-
synuclein in mice treated with PGJ2
In mice infused with DMSO and 3.4 μg of PGJ2 only low
levels of ubiquitinated proteins were detected. The latter
(stained red) exhibited a diffuse distribution throughout
the cytoplasm of the TH-positive cells (stained green) in
the SNpc (Fig. 5A). Infusion of 6.7 μg and 16.7 μg of PGJ2
caused the formation of intracellular aggregates of ubiqui-
tinated proteins observed in the few spared TH-positive
neurons in the SNpc (Fig. 5A and 5B). TH immunostain-
ing (green) co-localized with the ubiquitin aggregates (red)
suggesting that the enzyme is trapped in the aggregates
containing ubiquitinated proteins.
In cells containing protein aggregates (Fig. 5B, arrows)
nuclei exhibit the typical morphology associated with
apoptosis, i.e. a condensed or fragmented appearance
(Fig. 5B, arrowheads). This nuclear morphology suggests
that cells exhibiting protein aggregates are committed to
the apoptotic pathway.
We investigated if PGJ2 infusion causes changes in α-
synuclein distribution in the SNpc. Immunostaining with
antibodies to α-synuclein (Fig. 6) revealed immunoreac-
tive aggregates in TH+ neurons in SNpc in mice treated
with the highest PGJ2 concentration (16.7 μg). This was
not surprising, since we previously demonstrated that
PGJ2 induces the formation of α-synuclein aggregates in
human neuroblastoma SK-N-SH cells [26].
Representative coronal sections of the ventral midbrain showing TH-immunoreactive euronsFigure 2
Representative coronal sections of the ventral mid-
brain showing TH-immunoreactive neurons. TH-
immunoreactivity was strong in VTA and SNpc of control 
(DMSO) mice and mice treated with 3.4 μg PGJ2 (two top 
panels), but decreased in a concentration-dependent manner 
in the right SNpc (ipsilateral to the lesion) of mice treated 
with 6.7 μg or 16.7 μg of PGJ2 (two bottom panels).
PGJ2 dose-dependent loss of dopaminergic neurons in the SNpcFigure 3
PGJ2 dose-dependent loss of dopaminergic neurons 
in the SNpc. TH (red, dopaminergic neurons) and NeuN 
(green, all neurons) immunostaining of SN shows a dose-
dependent loss of dopaminergic neurons after microinjec-
tions with 6.7 μg or 16.7 μg of PGJ2. No dopaminergic neu-
ronal loss was observed in the side contralateral to the 
injection site. Scale bar = 20 μm. The table lists TH+ cell 
counts in ipsilateral SNpc slices of DMSO- and PGJ2(16.7 
μg)-infused mice determined as described under Methods.
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Increase microglia and astrocyte activation in the SNpc in 
response to PGJ2
Our studies demonstrate that in mice infused with 6.7 μg
and 16.7 μg of PGJ2 there is a potent activation of micro-
glia (Fig. 7) as well as astrocytes (Fig. 8).
Behavioral changes induced by PGJ2
To address the posture and walking difficulties associated
with PD, four weeks after the last injection we performed
simple behavioral tests in control and PGJ2-treated mice
(Fig. 9). It is clear that mice treated with 16.7 μg PGJ2
exhibited severe postural instability, consistent with a uni-
lateral lesion. All of the mice in this group displayed ipsi-
lateral curling (Fig. 9A). No asymmetry was observed in
the other groups. Mice treated with the highest PGJ2 con-
centration also showed gait impairment assessed by foot-
print patterns, in particular step frequency and stride
length (Fig. 9B and 9C). In addition, mice that were uni-
laterally microinfused with 16.7 μg of PGJ2 experienced
moderate turning behavior (mean 9.0 ± 4.6 rotations/10
min) when administered apomorphine, a DA receptor
agonist. Induction of turning occurred within minutes
after drug injection. Apomorphine-induced turning was
only elicited in the animals that received the highest dose
of PGJ2 because they experienced the most substantial
lesion to the nigrostriatal pathway. It is well established
that with moderate lesions (<80%), no asymmetry occurs
[25].
Discussion
Herein, we demonstrate in vivo that infusion of PGJ2 into
the substantia nigra and striatum in mice induces a dose-
dependent degeneration of dopaminergic neurons in the
SNpc. Due to depletion of dopamine-producing neurons
in the basal ganglia, individuals with PD experience dete-
rioration in balance and postural control as well as a pro-
gressive reduction in the speed and amplitude of
movements. The behavioral tests performed in control
and PGJ2-treated mice clearly indicate that PGJ2-treated
mice exhibit gait impairment, severe postural instability
and moderate turning behavior, the latter upon apomor-
phine administration supporting a basal ganglia lesion.
Notably, the GABAergic neurons in the neighboring sub-
stantia nigra pars reticulata (SNpr) were not affected by the
GABAergic neurons in the SNpr are spared in PGJ2-treated miceFigure 4
GABAergic neurons in the SNpr are spared in PGJ2-
treated mice. TH (green, dopaminergic) and glutamic acid 
decarboxylase (GAD-67) staining (red, GABAergic) immu-
nostaining of SN shows a dose-dependent loss of dopaminer-
gic but not of GABAergic neurons after microinjections with 
6.7 μg or 16.7 μg of PGJ2. The ellipse indicates the SNpr. 
The star indicates the site of injection. Scale bar = 100 μm.
Aggregates with ubiquitinated proteins are detected upon PGJ2 infusionFigure 5
Aggregates with ubiquitinated proteins are detected 
upon PGJ2 infusion. A & B. Immunostaining for ubiquiti-
nated proteins (red) and TH-positive neurons (green) was 
performed four weeks after the last PGJ2 microinjection. 
Dopaminergic neurons in the SNpc of mice treated with 6.7 
μg or 16.7 μg of PGJ2 exhibited clear aggregates (arrows) 
with ubiquitinated proteins. Nuclear staining (Hoechst) in the 
mice treated with the two highest doses of PGJ2 also exhibit 
an apoptotic morphology, i.e. a fragmented and/or con-
densed appearance (arrowheads). No difference was apparent 
between DMSO-treated mice and mice treated with the low-
est PGJ2 concentration (3.4 μg). Panels with brackets depict 
ipsilateral (infused) and contralateral sections of the same 
mouse. Scale bar = 20 μm in A and 10 μm in B.
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PGJ2 microinfusions. It is thus likely that dopaminergic
neurons of the SNpc are selectively vulnerable to the toxic
actions of PGJ2. At least two reasons can explain why
dopaminergic neurons are more susceptible to PGJ2 tox-
icity. Firstly, PGJ2 up-regulates the expression and
increases the activity of COX-2 in cultured neuronal cells
[27]. COX-2 readily uses dopamine as an electron donor
and in so doing forms the highly cytotoxic dopamine qui-
none (DAQ) [28]. Secondly, PGJ2 potentiates dopamine
toxicity in neuronal cultures by attenuating catechol-O-
methyltransferase activity [29]. In this way, PGJ2 increases
the cytoplasmic availability of dopamine which, in excess
of the buffering capacity of the cytosol, will further
enhance the production of cytotoxic DAQ. DAQ cova-
lently binds to intracellular proteins, including α-synu-
clein, leading to the accumulation of pathogenic
protofibrils [30].
The ventral tegmental area (VTA), which is in the vicinity
of the SN, also contains dopaminergic neurons. However,
the VTA dopaminergic neurons were not affected by the
PGJ2-treatment, most likely because they are further away
from the site of injection and may not be exposed to the
toxin. Prostaglandins of the J2 series are highly reactive
lipid electrophiles that act as potent local regulators in an
autocrine or paracrine manner [31]. Assessment of the
susceptibility of the VTA dopaminergic neurons to PGJ2-
toxicity may require a similar microinjection paradigm to
be applied to this site. The fact that some of the products
of inflammation, such as PGJ2, exert their effects in a
localized autocrine or paracrine manner could explain
why different forms of neurodegenerative disorders, such
as AD and PD, share a common mechanism, i.e. neuroin-
flammation, because the disease form would depend on
where in the CNS the pro-inflammatory event takes place.
Thus, the variety of disease manifestations associated with
neuroinflammation could be correlated with the primary
brain region affected by the injurious event, its severity
and duration.
Overexpression of α-synuclein increases the risk of spo-
radic PD, while α-synuclein mutations are associated with
inherited PD [32]. Lewy bodies, which are characteristic of
Aggregates with α-synuclein are detected upon PGJ2 infusionFigure 6
Aggregates with α-synuclein are detected upon PGJ2 
infusion. Immunostaining for α-synuclein (green) and TH-
positive neurons (red) was performed four weeks after the 
last PGJ2 microinjection. Dopaminergic neurons in the SNpc 
of mice treated with 16.7 μg of PGJ2 exhibited clear aggre-
gates (arrows) with α-synuclein. Panels with brackets depict 
ipsilateral (infused) and contralateral sections of the same 
mouse. Scale bar = 20 μm.
PGJ2 dose-dependent microglia activation in the SNFigure 7
PGJ2 dose-dependent microglia activation in the SN. 
TH (red, dopaminergic) and IBA1 (green, activated microglia) 
immunostaining of SN shows a dose-dependent loss of 
dopaminergic neurons coinciding with microglia activation 
caused by treatment with the two highest PGJ2 concentra-
tions (6.7 μg or 16.7 μg). No difference was apparent 
between DMSO-treated mice and mice treated with the low-
est PGJ2 concentration (3.4 μg). Panels with brackets depict 
ipsilateral (infused) and contralateral sections of the same 
mouse. Scale bar = 20 μm.
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PD contain ubiquitinated proteins and also α-synuclein.
Distinct aggregates of ubiquitinated proteins and α-synu-
clein were observed in the few detectable dopaminergic
neurons in the SNpc of mice infused with the highest con-
centration of PGJ2 (16.7 μg). In other PD models such as
the acute MPTP and the 6-OHDA models, no inclusions
with ubiquitinated proteins were identified (reviewed in
[6]), pointing to an advantage of the PGJ2 model. How-
ever, continuous MPTP-infusion (treatment for 28 days)
also triggered formation of nigral ubiquitin immunoreac-
tive inclusions [33]. It is not surprising that we observed
ubiquitin-protein aggregates in mice infused with PGJ2.
Data from our laboratory and others clearly demonstrate
that PGJ2 impairs the ubiquitin/proteasome pathway
(UPP). These endogenous electrophiles (1) inhibit ubiq-
uitin isopeptidase activity [34] as well as ubiquitin hydro-
lases UCH-L1 and UCH-L3 [35], (2) induce the formation
of cysteine-targeted thyolation of UCH-L1 [36] and of
PGJ2/proteasome conjugates [37], (3) trigger the oxida-
tion of the S6 ATPase subunit of the 26S proteasome [36],
and disrupt 26S proteasome assembly [38]. All of these
effects on the UPP promote the build-up of pro-apoptotic
and detrimental proteins, such as p53 and ubiquitinated
proteins [12]. In fact, cell culture studies demonstrated
that PGJ2 induces apoptosis [39-41] and inhibits mito-
chondrial activity [42-44].
We show that PGJ2 induces microglia and astrocyte acti-
vation in the SNpc. Notably, ubiquitin-protein aggregates
were observed only in dopaminergic neurons and not in
GABAergic neurons nor in glia. Microglia activation is
linked to an increase in proteasome activity, which par-
tially explains why microglia are resistant to the large
amounts of oxygen free radicals that they produce once
activated [45]. This same phenomenon of proteasome
activation may protect microglia from the toxic effects of
PGJ2. Interestingly, microglia activation is required for
their uptake of apoptotic material which is degraded by
both the proteasomal and the lysosomal pathways with
the proteasome being the major player [46].
The observation that PGJ2-infusion leads to a potent acti-
vation of microglia as well as astrocytes, suggests that
PGJ2 could be a driving force for progressive dopaminer-
gic neurodegeneration. Although activated microglia and
astrocytes release trophic factors, most of their released
products are pro-inflammatory and potently cytotoxic [4].
The PGJ2-dependent glial activation may thus be instru-
mental in further exacerbating the neurodegenerative
process observed in PD.
PGJ2 is derived from PGD2, the major prostaglandin pro-
duced in the CNS [47,48]. PGD2 is very short lived and
readily undergoes in vivo and in vitro non-enzymatic dehy-
dration to generate the biologically active cyclopentenone
J2 prostaglandins, which include PGJ2, Δ12-PGJ2 and 15-
deoxy-Δ12,14-PGJ2 (15d-PGJ2) [49]. A noteworthy
review suggested that "formation of cyclopentenone
eicosanoids [such as PGJ2] in the brain may represent a
novel pathogenic mechanism that contributes to many
neurodegenerative conditions" [50]. The response to
PGJ2 is different from that of agonists that do not form
covalent adducts with proteins. A slow steady stream-like
release of PGJ2 as a result of chronic neuroinflammation
is bound to be cumulative, leading overtime to accumula-
tion of covalent protein adducts with PGJ2 until they
reach a toxic threshold. PGJ2 is thus a highly reactive elec-
trophiles that can lead to progressive neurodegeneration
[51].
PGJ2 dose-dependent astrocyte activation in the SNFigure 8
PGJ2 dose-dependent astrocyte activation in the SN. 
TH (red, dopaminergic) and glial fibrillary acidic protein 
(GFAP, blue, activated astrocytes) immunostaining of SN 
shows a dose-dependent loss of dopaminergic neurons con-
curring with astrocyte activation caused by treatment with 
the two highest PGJ2 concentrations (6.7 μg or 16.7 μg). No 
difference was apparent between DMSO-treated mice and 
mice treated with the lowest PGJ2 concentration (3.4 μg). 
Panels with brackets depict ipsilateral (infused) and contralat-
eral sections of the same mouse. Scale bar = 20 μm.
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Another product of inflammation, nitric oxide, has a half
life of just a few seconds and yet is well accepted as a
major signaling molecule in neurons and in the immune
system [52]. The same can be said for PGJ2, i.e. that it is a
major signaling molecule/oxidative stress agent. Like
nitric oxide, PGJ2 has a dual nature: it is protective at low
concentrations but toxic at higher concentrations [12].
The synthetic tetrazole HQL-79 is a selective inhibitor of
the hematopoietic prostaglandin D2 synthase (H-PGDS)
an enzyme that generates PGD2, the precursor of PGJ2.
HQL-79 was prepared as an anti-histamine to block the
inflammatory signal mediated by both PGD2 receptors,
DP1 and DP2 [53]. Selective inhibitors of H-PGDS are
more useful to suppress inflammatory reactions than
COX-1 and COX-2 inhibitors, because they will not halt
production of all PGs, including the cytoprotective and
anti-inflammatory ones [53]. These inhibitors do not alter
the metabolic flow within the PG cascade, thus do not
change the total amount of PGs [53]. Interestingly, HQL-
79 suppresses astrogliosis following stab-wounding brain
injury [53], suggesting that it could be an excellent anti-
inflammatory lead compound against a variety of diseases
associated with inflammation.
Conclusion
We conclude that subchronic microinfusion of PGJ2 into
the substantia nigra/striatum induces pathological features
similar to the ones observed in PD neurodegeneration
including (a) dopaminergic degeneration in the SNpc, (b)
formation of intracellular aggregates of ubiquitinated pro-
teins and α-synuclein, (c) microglia and astrocyte activa-
tion and (d) behavioral changes. The chemical properties
of PGJ2 and its pro-oxidant and UPP disrupting effects
render PGJ2 extremely neurotoxic and capable of induc-
ing neuronal cell death [12]. Overall, we propose that the
chronic production of neurotoxic products of inflamma-
tion (such as PGJ2) will lead to a self-propelling glial
(microglia and astrocytes) activation that could be a driv-
ing force for progressive dopaminergic neurodegenera-
tion. Over time, this feed-forward cycle of glial activation
and neuronal injury would result in sufficient degenera-
tion of the nigrostriatal dopaminergic pathway to lead to
the development of symptomatic PD. It cannot be ruled
out that glial activation also has neuroprotective effects.
Therefore, glial activation may represent a double-edged
sword and its role on the neurodegenerative process needs
to be further addressed.
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Symptoms of motor dysfunction in mice treated with the highest PGJ2 concentration (16.7 μg)Figure 9
Symptoms of motor dysfunction in mice treated with the highest PGJ2 concentration (16.7 μg). PGJ2 causes 
severe postural instability (A) and gait impairment (B). The curling test evaluates any asymmetry in body posture. There is a 
severe deviation from the vertical body axis in PGJ2 treated animals. Representative walking footprint patterns display irregular 
step pattern, decrease in step frequency and increase in stride length (C, graph) in the PGJ2-treated animals. The asterisk (*) 
identifies the values that are significantly different (p < 0.01, ANOVA, Tukey-Kramer multiple comparison test) from the con-
trol (DMSO).
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